Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen versus aspirin + dabigatran in stable coronary artery disease with atrial fibrillation
ChiCTR2000029015Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Indobufen, aspirin and dabigatran in coronary arteriosclerosis and Atrial fibrillation (AFib) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Treadmill exercise testing load, Serum D-dimer and 2 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
Indobufenaspirindabigatran
03
Conditions
coronary arteriosclerosisAtrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2000029015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029015.